EMEA-001904-PIP02-17
Key facts
| Active substance |
Brincidofovir
|
| Therapeutic area |
Infectious diseases
|
| Decision number |
P/0348/2018
|
| PIP number |
EMEA-001904-PIP02-17
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of adenovirus in immunocompromised patients
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
SymBio Pharmaceuticals Limited
E-mail: mkano.mk11@symbiopharma.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|